| Literature DB >> 35501067 |
Racha Fadlallah1,2,3, Najla Daher3, Amena El-Harakeh2,4, Rima Hammam2, Hneine Brax5, Lama Bou Karroum1,2,3, Luciane Cruz Lopes6, Ghida Arnous2, Inas Kassamany2, Stephanie Baltayan2, Aya Harb2, Tamara Lotfi4, Fadi El-Jardali1,2,3, Elie A Akl7,4,8.
Abstract
OBJECTIVE: To systematically identify and describe approaches to prioritise primary research topics in any health-related area.Entities:
Keywords: Health policy; Health services research; Health systems; Public Health; Review
Mesh:
Year: 2022 PMID: 35501067 PMCID: PMC9062777 DOI: 10.1136/bmjgh-2021-007465
Source DB: PubMed Journal: BMJ Glob Health ISSN: 2059-7908
Figure 1Study selection process.
General characteristics of the 25 included approaches
| Characteristics | Description | N (%) | Referencing |
| Setting | High income | 17 (68) | |
| Middle income | 2 (8) |
| |
| Low income | – | – | |
| Not reported | 6 (24) | ||
| Field† | Clinical | 10 (40) | |
| Health policy and systems | 9 (36) | ||
| Public health | 6 (24) | ||
| Health in general | 9 (36) | ||
| Health services research | 5 (20) | ||
| Level of prioritisation† | Institutional | 7 (28) | |
| Subnational | 7 (28) | ||
| National | 20 (80) | ||
| Regional | 5 (20) | ||
| International | 7 (28) | ||
| Funding† | Governmental | 10 (40) | |
| Intergovernmental | 2 (8) |
| |
| Private not for profit | 6 (24) | ||
| Private for profit | – | – | |
| Not reported | 10 (40) | ||
| Type of publication | Peer review | 18 (72) | |
| Grey literature | 7 (28) |
*More than one study reporting on the same approach.
†Percentages add up to more than 100% as more than one option applies.
Steps of the development of the prioritisation approaches (N=22)
| Use of a pre-existing approach | Literature review | Consensus building | Stakeholder input | Pilot-testing | |
| N (%) approaches reporting the step | 14 (64) | 14 (64) | 3 (14) | 7 (32) | 11 (50) |
| Abma, 2010 | ✓ | ✓ | ✓ | ||
| Ball, 2016 | ✓ | ✓ | ✓ | ||
| Bennett, 2010; Bennett, 2012; Saldanha, 2013 | ✓ | ✓ | |||
| Berra, 2010 | ✓ | ✓ | ✓ | ✓ | ✓ |
| Chang, 2012 | ✓ | ✓ | ✓ | ||
| Chapman, 2013 | ✓ | ||||
| Cowan, 2013 | ✓ | ||||
| Dubois, 2011 | ✓ | ✓ | ✓ | ||
| Edwards, 2019 | ✓ | ||||
| Franck, 2018; Franck, 2020 | ✓ | ||||
| Ghaffar, 2009; 2009 | ✓ | ✓ | ✓ | ||
| Hacking, 2016 | ✓ | ✓ | |||
| Kapiriri, 2018 | ✓ | ✓ | ✓ | ✓ | |
| Lomas, 2003 | ✓ | ✓ | |||
| Montorzi, 2010 | ✓ | ✓ | |||
| Pratt, 2016 | ✓ | ||||
| Rudan, 2006, 2008 | ✓ | ✓ | |||
| Somanadhan, 2020 | ✓ | ✓ | |||
| Viergever, 2010 | ✓ | ✓ | ✓ | ||
| Wald, 2014 | ✓ | ||||
| WHO, 1996 | ✓ | ✓ | |||
| Yan, 2020 | ✓ | ✓ |
*The denominator reflects the total number of approaches that described the steps of the development of the approach.
†The tool has now been further refined into a Three-Dimensional Combined Approach Matrix which is described in this document.
Aspects to be addressed in the prioritisation process, as proposed by the approaches (N=25)
| Situation analysis/environmental scan | Methods for generation of initial list of topics | Use of prioritisation criteria | Stakeholder engagement | Description of ranking process/ technique | Dissemination and implementation | Revision or appeal mechanism | Monitoring and evaluation | |
| N (%) approaches reporting the aspect | 7 (28) | 19 (76) | 18 (72) | 23 (92) | 18 (72) | 16 (64) | 10 (40) | 10 (40) |
| Abma, 2010 | ✓ | ✓ | ✓ | |||||
| Ball, 2016 | ✓ | ✓ | ✓ | ✓ | ||||
| Bennett, 2010; Bennett, 2012; Saldanha, 2013 | ✓ | ✓ | ✓ | ✓ | ||||
| Berra, | ✓ | ✓ | ✓ | |||||
| Carson, 2000 | ✓ | |||||||
| Chang, 2012 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||
| Chapman, 2013 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||
| Cowan, 2013 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Dubois 2011 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||
| Edwards, 2019 | ✓ | ✓ | ✓ | ✓ | ✓ | |||
| Franck, 2018; Franck, 2020 | ✓ | ✓ | ✓ | ✓ | ||||
| Ghaffar, 2009; 2009 | ✓ | ✓ | ✓ | ✓ | ✓ | |||
| Hacking, 2016 | ✓ | ✓ | ||||||
| Kapiriri, 2018 | ✓ | ✓ | ✓* | ✓ | ✓ | ✓ | ✓ | ✓ |
| Lomas, 2003 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||
| Montorzi, 2010 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |
| NIH | ✓ | ✓ | ✓ | ✓ | ||||
| Okello, 2000; Lansang 1997 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Pratt, 2016 | ✓ | ✓* | ✓ | ✓ | ||||
| Rudan, 2008 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||
| Somanadhan, 2020 | ✓ | ✓ | ✓ | ✓ | ||||
| Viergever, 2010 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Wald, | ✓ | ✓ | ✓ | ✓ | ✓ | |||
| WHO, | ✓ | ✓ | ||||||
| Yan, 2020 | ✓ | ✓ | ✓ | ✓ |
*In this approach, ‘ importance’ and ‘feasibility’ were proposed as prioritisation criteria, but authors only considered the score for ‘importance’ when generating the top priorities.
†These approaches indicated the use of prioritisation criteria but did not propose criteria.
Methods proposed for generating initial list of topics (N=19)
| Literature review/scan | Research gaps from existing systematic reviews/guidelines | Health information system | Stakeholder inputs | Previous priority-setting exercises | |
|
| 9 (47) | 7 (37) | 4 (21) | 16 (84) | 3 (16) |
| Abma, 2010 | ✓ | ✓ | |||
| Ball, 2016 | ✓ | ✓ | |||
| Bennett, 2010; Bennett, 2012; Saldanha, 2013 | ✓ | ✓ | |||
| Chang, 2012 | ✓ | ✓ | ✓ | ||
| Chapman, 2013 | ✓ | ||||
| Cowan, 2013 | ✓ | ✓ | |||
| Ghaffar, 2009; 2009 | ✓ | ✓ | ✓ | ||
| Edwards, 2019 | ✓ | ||||
| Franck, 2018; Franck, 2020 | ✓ | ✓ | |||
| Kapiriri, 2018 | ✓ | ✓ | |||
| Lomas, 2003 | ✓ | ✓ | ✓ | ✓ | |
| Montorzi, 2010 | ✓ | ✓ | |||
| Okello, 2000; Lansang, 1997 | ✓ | ✓ | ✓ | ||
| Pratt, 2016 | ✓ | ||||
| Rudan, 2008 | ✓ | ||||
| Somanadhan, 2020 | ✓ | ✓ | |||
| Viergever, 2010 | ✓ | ✓ | |||
| Wald, 2014 | ✓ | ✓ | ✓ | ||
| Yan, 2020 | ✓ |
*Percentages add up to more than 100% as more than one option applies.
†Initial topics were generated from existing systematic reviews and guidelines.
Framework for prioritisation domains and criteria (N=15)
| Prioritization | N (%)* | Berra | Carson | Chang | Chapman | Dubois | Ghaffar | Hacking | Lomas | NIH | Okello | Rudan | Somanadhan | Viergever | Wald | WHO |
| Problem-related considerations | ||||||||||||||||
| Health burden | 12 (80%) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||
| Economic burden | 3 (20%) | ✓ | ✓ | ✓ | ||||||||||||
| Equity considerations | 4 (27%) | ✓ | ✓ | ✓ | ✓ | |||||||||||
| Determinants of problem | 2 (13%) | ✓ | ✓ | |||||||||||||
| Practice considerations | ||||||||||||||||
| Variation in practice | 2 (13%) | ✓ | ✓ | |||||||||||||
| Uncertainty for decision-makers/ practitioners practitioners | 0 (0%) | |||||||||||||||
| Existing research base | ||||||||||||||||
| Availability of research on topic | 8 (53%) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||
| Usefulness of available research on topic | 1 (7%) | ✓ | ||||||||||||||
| Potential to change conclusions/advance research | 1 (7%) | ✓ | ||||||||||||||
| Amenability to research | ||||||||||||||||
| Topic amenability to research | 3 (20%) | ✓ | ✓ | ✓ | ||||||||||||
| Urgency | ||||||||||||||||
| Urgency | 5 (33%) | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||||
| Interest of the topic to: | ||||||||||||||||
| Health professionals | 3 (20%) | ✓ | ✓ | ✓ | ||||||||||||
| Patients/consumers | 4 (27%) | ✓ | ✓ | ✓ | ✓ | |||||||||||
| National stakeholders | 2 (13%) | ✓ | ✓ | |||||||||||||
| Regional/global stakeholders | 2 (13%) | ✓ | ✓ | |||||||||||||
| Implementation considerations | ||||||||||||||||
| Research capacity | 5 (33%) | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||||
| Applicability / utilization of research | 7 (47%) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||
| Availability of resources | 11 (73%) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||
| Political will | 3 (20%) | ✓ | ✓ | ✓ | ||||||||||||
| Sustainability | 3 (20%) | ✓ | ✓ | ✓ | ||||||||||||
| Community engagement | 2 (13%) | ✓ | ✓ | |||||||||||||
| Expected impact of applying evidence on | ||||||||||||||||
| Health policy & practice | 3 (20%) | ✓ | ✓ | ✓ | ||||||||||||
| Health outcomes | 9 (60%) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||
| Economic outcomes¶ | 10 (67%) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||
| Patient experience of care | 2 (13%) | ✓ | ✓ | |||||||||||||
| Equity | 4 (27%) | ✓ | ✓ | ✓ | ✓ | |||||||||||
| Development & broader society | 1 (7%) | ✓ | ||||||||||||||
| Ethical, human rights & moral considerations | ||||||||||||||||
| Ethical, human rights & moral considerations | 4 (27%) | ✓ | ✓ | ✓ | ✓ | |||||||||||
*The denominator reflects the total number of approaches that proposed specific criteria to be used as part of the priority setting.
†This approach listed some examples of criteria considered by Steering Groups to help reduce a list of indicative questions to a more manageable size for ‘interim’ prioritisation by external stakeholders.
‡Criteria were used by research experts to translate priority issues identified by stakeholders during consultations into priority research themes.
§While two criteria were proposed ‘importance’ and ‘feasibility’, authors only considered the score for ‘importance’ when generating the top priorities.
¶This encompasses cost-effectiveness of interventions.
Types of stakeholders proposed to be involved in prioritising primary research topics (N=22)
| Approach | Types of stakeholders | |||||||||||||
| Governments/ policy-makers | Healthcare providers | Researchers/ academia | Members of the public | Patients and their representatives | Caregivers | Health system payers | Healthcare managers | Intergovernmental agencies/ Research funders | Product makers/Industry | Press and media organisations | NGOs and advocacy groups | Internal staff | Other | |
|
| n=10 | n=16 | n=17 | n=9 | n=13 | n=7 | n=4 | n=2 | n=6 | n=3 | n=1 | n=8 | n=3 | n=6 |
| Abma, | ✓ | ✓ | ✓ | ✓ | ||||||||||
| Ball, 2016 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||
| Bennett, 2010; Bennett, 2012; Saldanha, 2013 | ✓ | ✓ | ✓ | ✓ | ||||||||||
| Berra, | ✓ | ✓ | ||||||||||||
| Chang, | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||
| Chapman, 2013 | ✓ | ✓ | ✓ | ✓ | ||||||||||
| Okello, 2000; Lansang 1997 | ✓ | ✓* | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||
| Cowan, 2013 | ✓* | ✓ | ✓ | ✓ | ✓ | |||||||||
| Dubois, 2011 | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||||
| Edwards, 2019 | ✓ | ✓ | ✓ | |||||||||||
| Franck, 2018; Franck, 2020 | ✓ | ✓ | ||||||||||||
| Ghaffar, 2009; 2009 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||
| Kapiriri, 2018 | ✓ | ✓ | ||||||||||||
| Lomas, 2003 | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||||
| Montorzi, 2010 | ✓** | |||||||||||||
| NIH, 2001 | ✓ | ✓† | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||
| Pratt, 2016 | ✓ | ✓ | ||||||||||||
| Rudan, 2008 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||
| Somanadhan, 2020 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||
| Viergever, 2010 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||
| Wald, 2014 | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||||
| Yan, 2020 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||
*The denominator reflects the total number of approaches that proposed stakeholder involvement as part of the priority setting.
†Includes professional associations.
The roles for the different types of stakeholders proposed to be involved in prioritising primary research topics (N=25)
| Types of stakeholders | Executive committee/ coordination | Theme identification phase | Establishment of initial list of topics | Refinement of topics/questions | Prioritisation/ Ranking of topics/questions | Selection of criteria and weighting method | Validation of prioritisation output | Process evaluation | Dissemination | Other |
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
| Public policy-makers | 3 (12%) | 3 (12%) | 3 (12%) | 1 (4%) | 6 (24%) | 1 (4%) | 1 (4%) | 1 (4%) | ||
| Healthcare providers | 5 (20%) | 10 (40%) | 10 (40%) | 1 (4%) | 13 (52%) | 3 (12%) | 2 (8%) | 1 (4%) | 1 (4%) | 1 (4%) |
| Researchers/academia | 7 (28%) | 8 (32%) | 7 (28%) | 3 (12%) | 10 (40%) | 3 (12%) | 1 (4%) | 1 (4%) | 1 (4%) | |
| Members of the public | 3 (12%) | 3 (12%) | 3 (12%) | 1 (4%) | 7 (28%) | 2 (8%) | 1 (4%) | |||
| Patients and their representatives | 5 (20%) | 9 (36%) | 10 (40%) | 2 (8%) | 12 (48%) | 1 (4%) | 1 (4%) | 1 (4%) | 1 (4%) | 1 (4%) |
| Caregivers | 1 (4%) | 3 (12%) | 4 (16%) | 5 (20%) | 1 (4%) | |||||
| Health system payers | 1 (4%) | 2 (8%) | 2 (8%) | 4 (16%) | 1 (4%) | |||||
| Research funders | 3 (12%) | 3 (12%) | 3 (12%) | 2 (8%) | 5 (20%) | 2 (8%) | 1 (4%) | |||
| Product makers/Industry | 2 (8%) | 2 (8%) | 1 (4%) | |||||||
| Press & media organisations | 1 (4%) | |||||||||
| NGOs and advocacy groups | 4 (16%) | 3 (12%) | 4 (16%) | 5 (20%) | 1 (4%) | 1 (4%) | 1 (4%) | |||
| Internal staff | 1 (4%) | 2 (8%) | 1 (4%) | 1 (4%) | 2 (8%) | 1 (4%) | ||||
| Healthcare managers | 1 (4%) | 1 (4%) | 1 (4%) | |||||||
| Other | 3 (12%) | 2 (8%) | 4 (16%) | 1 (4%) | 2 (8%) | 1 (4%) | 1 (4%) | 1 (4%) | 1 (4%) |